PTGX

PTGX Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. · NASDAQ
Market Closed
121.40
▼ ⁦-2.11%⁩ (-2.62)
Post-market121.400.00% (0.00)
Market Cap$7.9B
Beta1.79
52w Low52w High
77.00160.81
Last Week
⁦-7.29%⁩
Last Month
⁦-12.99%⁩
Last 3 Months
⁦-21.54%⁩
Last Year
⁦+45.84%⁩
Open on chart
Premium content
Fair Value
Current price⁦$121⁩
  • Analyst targets
    5 analysts
    ⁦$173⁩
    ⁦+43%⁩
    Range ⁦⁦$160⁩–⁦$190⁩⁩Typical for this method across large companies: ⁦+20%⁩
  • Value at the industry multiple
    Last 12 months' earnings × ⁦15.9⁩, median of 64 companies
    ⁦$75⁩
    ⁦−38%⁩
    Range ⁦⁦$29⁩–⁦$199⁩⁩

The floor: what the company is worth if growth stopped today

  • Value with no growth
    Today's after-tax operating profit, held flat forever, at a ⁦13.1%⁩ discount rate
    ⁦$46⁩
    ⁦−62%⁩

⁦62%⁩ of today's price is what a buyer pays for growth that has not happened yet.

1
methods value it above the price
0
methods near the price
1
methods value it below the price

10-year US Treasury yield ⁦5.04%⁩ as of ⁦2026-11-19⁩. Estimates computed from company data and analyst targets, not investment advice.

Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$700 / yr
Monthly plan
$99 / mo
Premium content
Which listings have analyst coverage?

EL7 refreshes analyst ratings and price targets for active company listings on Nasdaq, the New York Stock Exchange and NYSE American, including US-listed depositary receipts. Funds (including ETFs and mutual funds), OTC listings and listings on other exchanges are outside this coverage. Some eligible listings may have no published target or analyst call in the past 12 months.

EL7 checks for new ratings several times on weekdays, refreshes consensus targets on weekdays and updates monthly rating history once a month.

Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
  • P/E (TTM)
    25.72x
    5.82x46.58x
    Near median
  • Forward P/E
    Outlier
    —
  • EV / EBITDA
    21.95x
    3.71x29.64x
    Near median
  • FCF Yield
    1.4%
    -99.3%7.8%
    Strong
  • Revenue Growth YoY
    163.7%
    -48.8%73.2%
    Exceptional
  • EPS Growth YoY
    661.3%
    -103.1%98.8%
    Exceptional
  • Gross Margin
    99.5%
    15.1%89.4%
    Exceptional
  • ROIC
    36.0%
    -150.5%16.1%
    Exceptional
  • Net Debt / EBITDA
    -2.44x
    0.00x1.99x
    Net cash
  • Dividend Yield
    Pays no dividend
    —
  • Payout Ratio
    Pays no dividend
    —
  • Altman Z-Score
    79.47
    -17.7515.77
    Exceptional
Financial Analysis
Related News

Frequently Asked Questions

What is Protagonist Therapeutics, Inc. stock?▼

Protagonist Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Protagonist Therapeutics, Inc.?▼

You can buy Protagonist Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Protagonist Therapeutics, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Protagonist Therapeutics, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Protagonist Therapeutics, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.